In the news

In the clinic for Oct. 23, 2023

Original source here.

Company Product Description Indication Status
Exact Sciences Corp., of Madison, Wis. Cologuard Stool DNA test Colorectal cancer (CRC) Data from the pivotal BLUE-C trial showed the next-generation Cologuard test met all study endpoints, demonstrating 94% sensitivity for CRC at 91% specificity; the test was significantly more likely to detect cancer or precancer than fecal immunochemical testing (FIT) (94% vs. 67% and 43% vs. 23%, respectively)
Guardant Health Inc., of Palo Alto, Calif. Guardant Reveal Circulating tumor DNA blood test Colon cancer Initial results from the PEGASUS trial suggest Guardant Reveal may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer; 34% of patients with a positive liquid biopsy result after surgery had the cancer return, while only 10% of patients with a negative result experienced a relapse
Oncohost Ltd., of Binyamina, Israel Prophet test Proteomics-based decision-support tool Non-small-cell lung cancer Study examining the experimental and computational analytical validity of the test was published in the Journal of Pharmaceutical & Biomedical Analysis; a strong experimental precision and accuracy performance was observed; computational precision analysis displayed high consistency for repeated samples; cross-platform analysis supported the reliability of the examined proteomic assay


For more information about individual companies and/or products, see Cortellis.

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
T. (855) 950-2112

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
T. +972 485 37558

Please Note:
PROphet® NSCLC is currently available in all US states except NY